Background: Asthmatic patients with antibody deficiencies (AD) have more severe disease and higher risk of exacerbations. No data exist about the efficacy of biologics in severe asthma (SA) patients with AD.
Objective: To evaluate the efficacy of biologics in SA patients with and without AD.
Methods: A case-control real-life study was conducted including 68 patients divided into 2 groups: group 1 with SA-AD and group 2 with SA.
Results: Treatment with biologics for 6 months was effective for decreasing the number of exacerbations, hospitalizations, and emergency department (ED) visits and improving the Asthma Control Questionnaire (ACQ) score; biologics also proved a systemic corticosteroid-sparing effect. Despite benefits, the number of exacerbations, hospitalizations, and ED visits, the mean ACQ score, and the cumulative dose of systemic corticosteroids remain higher in group 1 than in group 2, with lower lung function parameters. The rates of responses in group 1 were inferior to those in group 2, with a decrease by ≥50% of exacerbation rate in 76% versus 97% of patients (P = .006), no hospitalization in 44% versus 91% of patients (P < .001), no ED visit in 56% versus 82% of patients (P = .018), a significant improvement of the ACQ score by ≥0.5 in 68% versus 100% of patients (P < .001), and an increase of forced expiratory volume in the first second by >10% in 32% versus 65% of patients (P = .007).
Conclusions: Despite evident benefits, SA patients with AD have suboptimal responses to biologics compared with those immunocompetent. A multidisciplinary approach is necessary to optimize the management of these patients in practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2024.03.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral and intranasal aspirin desensitisation for non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease.
Cochrane Database Syst Rev
January 2025
Department of Otorhinolaryngology, Amsterdam University Medical Centre, Amsterdam, Netherlands.
Background: NSAID-exacerbated respiratory disease (N-ERD) is a hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin or ibuprofen, accompanied by chronic rhinosinusitis (with or without nasal polyps) or asthma. The prevalence of hypersensitivity to NSAIDs is estimated to be 2%. The first line of treatment is the avoidance of NSAIDs.
View Article and Find Full Text PDFEarly and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study.
J Asthma Allergy
December 2024
Pulmonology Clinic, Cantonal Hospital Graubünden, Chur, Switzerland.
Purpose: Although studies have evaluated benralizumab, a monoclonal IL-5 receptor α antibody in severe eosinophilic asthma (SEA), in real-world settings, additional evidence is needed to further characterize its effectiveness in specific patient populations. Our study aimed to evaluate asthma control over 56 weeks in patients treated with benralizumab in Swiss real-world settings.
Patients And Methods: Conducted across 13 centres, this prospective, observational, non-interventional study involved 73 adults with physician confirmed SEA.
Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial.
Allergol Int
December 2024
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address:
Background: Biologics are integral in the management of severe asthma. As the effectiveness of the anti-IL-5 receptor antibody benralizumab in Japan remains elusive, this study aimed to assess its real-world effectiveness in Japanese patients with severe asthma.
Methods: This prospective, interventional, single-arm clinical trial was conducted across ten facilities in Japan between September 2020 and July 2022.
Worse lung function, more allergic sensitization but less blood eosinophilia in elderly patients with long-standing versus late-onset asthma.
J Asthma
December 2024
Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Background: Asthma in the elderly is usually considered homogeneous and non-atopic.
Objective: To compare clinical, functional and immunological features between elderly asthmatics with long-standing asthma (LSA) and those with late-onset asthma (LOA).
Methods: Eighty-two asthmatics older than 64 were included into LSA (asthma onset before age 40; = 46) and LOA (asthma onset from 40 years of age on; = 36) groups.
Enhancing Emotion Regulation and Overcoming Craving in Alcohol Dependence Syndrome Through Mindfulness-based Relapse Prevention.
Indian J Psychol Med
May 2024
Dept. of Clinical Psychology, Faculty of Behavioural Sciences (FBS), Shree Guru Gobind Singh Tricentenary University (SGT University), Gurugram, Haryana, India.
Background: Alcohol dependence syndrome (ADS) is a significant challenge for psychologists due to relapse and its impacts on well-being. Mindfulness-based relapse prevention (MBRP) has emerged as a potential solution, receiving increasing attention in the field of psychological interventions for ADS. This study aimed to evaluate the impact of MBRP, specifically on emotion regulation and alcohol craving as primary outcomes, alongside the secondary consideration of assessing changes in mindfulness levels.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!